MondayApr 14, 2008 6:47 am
AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, released news earlier this morning on a planned interim analysis of its ongoing ANDES Phase 3 clinical trial of AGI-1067 for the treatment of Type 2 diabetes. The on-going study of 806 patients who completed three months in the study showed dose-related, statistically significant reductions in A1c. Final results are expected later on this year. “The ANDES trial is ongoing and we must await final data before drawing firm conclusions," commented Alexander Fleming, M.D., acting Chief Medical Officer. "We are encouraged by these early results,…
Continue Reading